US FDA extends review of KalVista’s swelling disorder drug due to heavy workload

US FDA extends review of KalVista's swelling disorder drug due to heavy workloadSource: Reuters
أخبار الاستثمار والأسواق المالية من موقع Investing.com
US FDA extends review of KalVista's swelling disorder drug due to heavy workloadSource: Reuters
Dana stock rating placed on CreditWatch positive by S&P amid sale of off-highway businessSource: Investing.com
Edgewell Personal Care credit outlook revised to negative by S&P on tariff concernsSource: Investing.com
ServiceNow credit rating upgraded to A2 by Moody's on strong growth outlookSource: Investing.com
Weather being monitored before Trump's military parade, Pentagon saysSource: Reuters
Amazon's healthcare business to be divided into six units after losing top health executivesSource: Reuters
Fed to release annual bank stress test results on June 27Source: Investing.com
U.S. Senate Republicans add judicial restriction to tax and spending billSource: Investing.com
Air India 787-8 accident - What we know so farSource: Investing.com
McDonald's settles $10 billion lawsuit with Byron Allen over ad spendingSource: Investing.com